NASDAQ:CORI - Corium International Stock Price, Forecast & News

Corium International trades on the NASDAQ under the ticker symbol "CORI."

Corium International Inc (NASDAQ:CORI) posted its earnings results on Thursday, August, 9th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks' consensus estimate of ($0.38) by $0.04. The biopharmaceutical company had revenue of $7.67 million for the quarter, compared to analysts' expectations of $6.72 million. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. View Corium International's Earnings History.

News articles about CORI stock have been trending very negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Corium International earned a media sentiment score of -4.0 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for Corium International.

Some companies that are related to Corium International include Turning Point Therapeutics (TPTX), Xencor (XNCR), Pacira Biosciences (PCRX), BELLUS Health (BLUSF), Heron Therapeutics (HRTX), IGM Biosciences (IGMS), Ligand Pharmaceuticals (LGND), Arvinas (ARVN), Tricida (TCDA), Alder Biopharmaceuticals (ALDR), Zymeworks (ZYME), Akcea Therapeutics (AKCA), Corcept Therapeutics (CORT), Aimmune Therapeutics (AIMT) and Constellation Pharmaceuticals (CNST).

Based on aggregate information from My MarketBeat watchlists, some companies that other Corium International investors own include Intelsat (I), Aralez Pharmaceuticals (ARLZ), Iovance Biotherapeutics (IOVA), Cypress Semiconductor (CY), Exelixis (EXEL), Energy Transfer LP Unit (ET), Global Blood Therapeutics (GBT), AMC Entertainment (AMC), SunCoke Energy Partners (SXCP) and Applied Materials (AMAT).

Corium International has a market capitalization of $0.00 and generates $31.86 million in revenue each year. The biopharmaceutical company earns $-47,790,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. View Additional Information About Corium International.

The official website for Corium International is http://www.coriumgroup.com/.

Corium International's mailing address is 235 CONSTITUTION DRIVE, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-298-8255 or via email at [email protected]